株探米国株
日本語 英語
エドガーで原本を確認する
false 0001948455 0001948455 2025-05-12 2025-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 12, 2025

 

Ispire Technology Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41680   84-5106049
(State or other jurisdiction
of incorporation or organization)
  (Commission file number)   (IRS Employer
Identification No.)

 

19700 Magellan Drive

Los Angeles, CA 90502

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (310) 742-9975

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ISPR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 


Item 2.02. Results of Operations and Financial Condition.

 

On May 12, 2025, Ispire Technology Inc. (the “Company”) issued a press release regarding its financial results for the fiscal second quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in that filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K:

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release of Ispire Technology issued on May 12, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ispire Technology Inc.
     
  By: /s/ Michael Wang
    Name: Michael Wang
    Title: Co-Chief Executive Officer
     
Dated: May 12, 2025    

 

 

 

 

EX-99.1 2 ea024166101ex99-1_ispire.htm PRESS RELEASE OF ISPIRE TECHNOLOGY ISSUED ON MAY 12, 2025

Exhibit 99.1

 

Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2025

Accounts Receivable Decreased from $67.7M to $60.4M Improving Company Financial Position

Post-Quarter End, IKE Tech Filed PMTA with the FDA for its Age-Gating Joint Venture Component with IKE

Launched SproutTM in Collaboration with Raw Garden, an Advanced All-In-One Cannabis Vapor Device Ensuring Purity and Safety

 

LOS ANGELES, May 12, 2025 – Ispire Technology Inc. (NASDAQ: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2025, for the three months ending March 31, 2025.

 

Fiscal Third Quarter 2025 Financial Results

 

Revenue of $26.2 million versus $30.0 million for the third quarter of fiscal 2024.
     
Gross profit of $4.8 million compared to $6.1 million for the third quarter of fiscal 2024.
     
Gross margin of 18.2% compared to 20.4% for the third quarter of fiscal 2024.
     
Total operating expenses of $15.4 million compared to $11.8 million for the third quarter of fiscal 2024.
     
Net loss of ($10.9) million, compared to net loss of ($5.9) million in the third quarter of fiscal 2024.

 

“The progress the Company made during the third fiscal quarter demonstrates that we are delivering on our promises and executing on our strategic priorities to become a leading global provider of precision dosing vape technology,” commented Michael Wang, Co-Chief Executive Officer of Ispire. “We have made significant strides as we are transitioning our manufacturing to Malaysia, effectively de-risking our production strategy for the current geopolitical climate. During the third fiscal quarter, in an effort to further streamline our operations and increase margins, we moved a number of our daily functions to our Malaysian campus which we anticipate will reduce our operating expenses by $8 million annually. During this restructuring and manufacturing transitional period, we took a measured approach to revenue so that customers are not adversely affected by our internal change-over. Another milestone also was our reduction in accounts receivable which happened for the first time in Ispire’s history. We took the necessary steps this quarter to focus on higher quality customers, including larger MSOs which helped bolster our overall financial position.”

 

“We also received an interim license for manufacturing nicotine products in Malaysia, and we anticipate the final license to be received over the coming few months. Once received, Ispire will have the first federal nicotine manufacturing license in Malaysia and will further position the Company as a leading international vaping hardware provider. Also, in conjunction with our joint venture partner, IKE Tech, we recently filed a component PMTA with the FDA for IKE’s innovative, blockchain-based point-of-use age-gating technology for ENDS products. If approved, this would mark the first component PMTA in FDA history for age verification technology and shows we are leading the way in preventing youth access. During the third quarter we were also excited to launch SproutTM in collaboration with Raw Garden. This advanced all-in-one cannabis vapor device was designed with purity and safety in mind, underscoring our commitment to consumer wellbeing,” Mr. Wang concluded.

 

 


 

Jim McCormick, Chief Financial Officer of Ispire, said, “Over recent quarters, Ispire has made a concerted effort to decrease our accounts receivable and improve our financial stability. In order to do so, we became laser focused on pursuing larger and higher-quality customers. The success we had in executing this strategy resulted in the Company reducing accounts receivable to $60.4 million vs. $67.7 million for the third fiscal quarter of the prior year. We remain steadfast in our commitment to driving shareholder value as we continue to focus on revenue generation, margin expansion and further reduction in our accounts receivable.

 

Financial Results for the Three and Nine-Month Periods Ended March 31, 2025

 

Ispire reported revenue of $26.2 million for the fiscal third quarter ended March 31, 2025, versus $30.0 million for the prior comparable period, a decrease of 12.7%. Ispire delivered revenue of $107.4 million for the nine-month period ended March 31, 2025, compared to $114.6 million during the same period in fiscal 2024, a decrease of 6.3%. The decline in revenue is largely due to a decrease in sales of vaping products in North America and a decrease in sales to the Asia Pacific region.

 

For the third quarter of fiscal 2025, gross profit was $4.8 million compared to $6.1 million in the year-ago period. Gross margin decreased to 18.2% compared to 20.4% for the third quarter of fiscal 2024. This was primarily due to changes in product mix with less margin products being sold during the three months ended March 31, 2025.

 

Gross profit for the nine-month period ended March 31, 2025, was $20.2 million while gross margin was 18.8%, versus $19.2 million and 16.8% respectively for the same period in the prior fiscal year. The growth in gross profit and gross margin for the nine months to March 31, 2025 was primarily due to changes in product mix, with more higher margin products being sold.

 

Total operating expenses were $15.4 million for the third fiscal quarter of 2025, compared to $11.8 million for the same period last year. For the nine-month period to March 31, 2025, operating expenses were $43.4 million, compared to $29.7 million in the same period in fiscal 2024. 

 

Net loss was $10.9 million or ($0.19) per share for the fiscal third quarter of 2025, versus a net loss of $5.9 million, or ($0.11) per share for the fiscal third quarter of 2024. For the first nine months of fiscal 2025, net loss was approximately $24.5 million or ($0.43) per share, versus a net loss of approximately $11.3 million, or ($0.21) per share in the first nine months of fiscal 2024.

 

At March 31, 2025, Ispire held cash and cash equivalents of $23.5 million and working capital of ($2.1) million.

 

2


 

Conference Call

 

The Company will conduct a conference call at 8:00am Eastern Time on Monday, May 12, 2025, to discuss the results, followed by a Q&A session.

 

To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

 

Date: Monday, May 12, 2025

 

Time: 8:00am ET

 

Dial-In Numbers: North America 888-880-3330 or International +1 646-357-8766

 

This conference call will be webcast live and can be accessed by all interested parties at https://app.webinar.net/z9kqo2ro81l.

 

Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

 

A playback will be available until 12:00 midnight Eastern Time on Thursday, May 15, 2025. To listen, please dial 800-770-2030 (Toll Free) or 609-800-9909 (Toll). Use the passcode 9733287 to access the replay.

 

About Ispire Technology Inc.

 

Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company’s website, any other website or any social media, is not a part of this press release.

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2024 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

 

3


 

ISPIRE TECHNOLOGY INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In $USD, except share and per share data)

 

    March 31,
2025
    June 30,
2024
 
Assets            
Current assets:            
Cash   $ 23,518,560     $ 35,071,294  
Restricted cash     72,594       -  
Accounts receivable, net     60,425,835       59,734,765  
Inventories     7,825,109       6,365,394  
Prepaid expenses and other current assets     2,184,559       1,400,152  
Total current assets     94,026,657       102,571,605  
Non-current assets:                
Property, plant and equipment, net     2,189,313       2,582,457  
Intangible assets, net     2,098,740       1,375,666  
Right-of-use assets – operating leases     5,356,384       3,579,140  
Other investment     2,000,000       2,000,000  
Equity method investment     9,841,020       10,248,048  
Other non-current assets     215,612       284,050  
Total non-current assets     21,701,069       20,069,361  
Total assets   $ 115,727,726     $ 122,640,966  
Liabilities and stockholders’ equity                
Current liabilities                
Accounts payable   $ 4,666,784     $ 3,779,723  
Accounts payable – related party     77,121,850       67,046,472  
Contract liabilities     1,561,842       2,218,166  
Accrued liabilities and other payables     10,033,739       11,738,339  
Bank loan – current portion     1,124,226       -  
Operating lease liabilities – current portion     1,667,641       1,207,832  
Total current liabilities     96,176,082       85,990,532  
                 
Non-current liabilities:                
Bank loan – net of current portion     1,215,136       -  
Operating lease liabilities – net of current portion     3,551,386       2,194,094  
Total liabilities     100,942,604       88,184,626  
                 
Commitments and contingencies                
                 
Stockholders’ equity:                
Common stock, par value $0.0001 per share; 140,000,000 shares authorized;  57,136,455 and 56,470,636 shares issued and outstanding as of March 31, 2025 and June 30, 2024     5,714       5,647  
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued at March 31, 2025 and June 30, 2024     -       -  
Treasury stock, at cost     (60,488 )     -  
Additional paid-in capital     48,141,075       43,217,391  
Accumulated deficit     (33,275,195 )     (8,825,041 )
Accumulated other comprehensive (loss) income     (25,984 )     58,343  
Total stockholders’ equity     14,785,122       34,456,340  
Total liabilities and stockholders’ equity   $ 115,727,726     $ 122,640,966  

 

4


 

ISPIRE TECHNOLOGY INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In $USD, except share and per share data)

 

    Three Months Ended
March 31,
    Nine Months Ended
March 31,
 
    2025     2024     2025     2024  
                         
Revenue   $ 26,190,725     $ 30,015,036     $ 107,356,898     $ 114,565,244  
                                 
Cost of revenue     21,414,820       23,893,083       87,184,044       95,345,545  
                                 
Gross profit     4,775,905       6,121,953       20,172,854       19,219,699  
                                 
Operating expenses:                                
Sales and marketing expenses     1,656,527       1,754,760       6,710,438       4,174,386  
General and administrative expenses     13,704,819       10,022,488       36,670,781       25,499,077  
                                 
Total Operating expenses     15,361,346       11,777,248       43,381,219       29,673,463  
                                 
Loss from operations     (10,585,441 )     (5,655,295 )     (23,208,365 )     (10,453,764 )
                                 
Other (expense) income:                                
Interest (expense) income, net     (32,166 )     27,296       3,138       298,161  
Exchange gain (loss), net     24,341       (53,904 )     (103,247 )     (19,387 )
Other (expense) income, net     (86,239 )     12,265       (47,906 )     20,078  
                                 
Total Other (expense) income, net     (94,064 )     (14,343 )     (148,015 )     298,852  
                                 
Loss before income taxes     (10,679,505 )     (5,669,638 )     (23,356,380 )     (10,154,912 )
                                 
Income taxes     (176,990 )     (255,485 )     (1,093,774 )     (1,103,710 )
                                 
Net loss   $ (10,856,495 )   $ (5,925,123 )   $ (24,450,154 )   $ (11,258,622 )
                                 
Other comprehensive loss                                
Foreign currency translation adjustments     (2,860 )     10,788       (84,327 )     169,578  
Comprehensive loss   $ (10,859,355 )   $ (5,914,335 )   $ (24,534,481 )   $ (11,089,044 )
                                 
Net loss per share                                
Basic and diluted   $ (0.19 )   $ (0.11 )   $ (0.43 )   $ (0.21 )
                                 
Weighted average shares outstanding:                                
Basic and diluted     57,003,488       54,347,729       56,752,454       54,287,624  

 

5


 

For more information, kindly contact:

 

IR Contacts:
Investor Relations
Sherry Zheng
718-213-7386
ir@ispiretechnology.com

 

KCSA Strategic Communications

Phil Carlson
212-896-1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
570-209-2947
EMellody@kcsa.com

 

 

6